Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers

ACS Chemical Biology

Volumn 8, Issue 9, 2013, Pages 1869-1875

  Molzan, Manuela ^a   Kasper, Stefan ^b   Röglin, Lars ^a   Skwarczynska, Malgorzata ^a   Sassa, Takeshi ^c   Inoue, Takatsugu ^d   Breitenbuecher, Frank ^b   Ohkanda, Junko ^d,e   Kato, Nobuo ^d   Schuler, Martin ^b,f   Ottmann, Christian ^a,g  

^a CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c YAMAGATA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; COTYLENIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MUTANT PROTEIN; NATURAL PRODUCT; PROTEIN 14 3 3; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CANCER GROWTH; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION;

14-3-3 PROTEINS; ANIMALS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; DITERPENES; HUMANS; MICE; MICE, SCID; MODELS, MOLECULAR; NEOPLASMS; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS C-RAF; RAF KINASES; RAS PROTEINS;

EID: 84884654621     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4003464     Document Type: Article

References (17)

1. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., and Ribas, A. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N. Engl. J. Med. 366, 707-714
2. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., and Rosen, N. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464, 427-430
3. Callahan, M. K., Rampal, R., Harding, J. J., Klimek, V. M., Chung, Y. R., Merghoub, T., Wolchok, J. D., Solit, D. B., Rosen, N., Abdel-Wahab, O., Levine, R. L., and Chapman, P. B. (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment N. Engl. J. Med. 367, 2316-2321
4. Dumaz, N. and Marais, R. (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras J. Biol. Chem. 278, 29819-29823
5. Tzivion, G., Luo, Z., and Avruch, J. (1998) A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity Nature 394, 536-539
6. Morrison, D. K. (2009) The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development Trends Cell Biol. 19, 16-23
7. +-ATPase by combining X-ray crystallography and electron cryomicroscopy Mol. Cell 25, 427-440
8. Ottmann, C., Weyand, M., Sassa, T., Inoue, T., Kato, N., Wittinghofer, A., and Oecking, C. (2009) A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A J. Mol. Biol. 386, 913-919
9. Molzan, M. and Ottmann, C. (2012) J. Mol. Biol. 423, 486-495
10. Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., and Schuler, M. (2012) Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade Oncogene 32, 2873-2881
11. Leijen, S., Middleton, M. R., Tresca, P., Kraeber-Bodéré, F., Dieras, V., Scheulen, M. E., Gupta, A., Lopez-Valverde, V., Xu, Z. X., Rueger, R., Tessier, J. J., Shochat, E., Blotner, S., Naegelen, V. M., Schellens, J. H., and Eberhardt, W. E. (2012) Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors Clin. Cancer Res. 18, 4794-4805
12. Wells, J. A. and McClendon, C. L. (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450, 1001-1009
13. Choi, J., Chen, J., Schreiber, S. L., and Clardy, J. (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273, 239-242
14. Thiel, P., Kaiser, M., and Ottmann, C. (2012) Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? Angew. Chem., Int. Ed. 51, 2012-2018
15. Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J., and Jackson, C. L. (1999) Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain Mol. Cell 3, 275-285
16. Rose, R., Erdmann, S., Bovens, S., Wolf, A., Rose, M., Hennig, S., Waldmann, H., and Ottmann, C. (2010) Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions Angew. Chem., Int. Ed. 49, 4129-4132
17. Milroy, L. G., Brunsveld, L., and Ottmann, C. (2012) Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study ACS Chem. Biol. 8, 27-35